Analyst Price Targets — OKUR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 10, 2024 6:12 am | Matt Biegler | Oppenheimer | $35.00 | $18.50 | TheFly | OnKure Therapeutics initiated with an Outperform at Oppenheimer |
Latest News for OKUR
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a…
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations
Shares of OnKure Therapeutics, Inc. (NASDAQ: OKUR - Get Free Report) have been assigned an average rating of "Hold" from the five analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OKUR.
U.S. House Trading
No House trades found for OKUR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.